CORTCorcept Therapeutics Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 13669
Ticker: CORT
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2004-04-14
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CORT

Detail

Enriched 2026-08-14 20:47

Market cap: $12,126,478,175.46
Shares outstanding (class): 108,098,397
Shares outstanding (weighted): 108,098,397
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 730
Location: REDWOOD CITY, CA
Homepage: https://www.corcept.com
Description: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Market cap and share counts drift.

Funds holding this security

164 funds · 165 positions · $944.62M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Core S&P Small-Cap ETF iShares Trust	IJR	$226.58M	0.25%	5,621,049 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$115.02M	0.01%	2,853,467 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$86.69M	3.82%	2,150,626 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$84.03M	0.05%	2,084,686 NS	FIGI
Fidelity Contrafund Fidelity Contrafund	—	$47.82M	0.03%	1,186,243 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$46.98M	0.12%	1,165,399 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$42.14M	0.05%	1,045,387 NS	FIGI
State Street(R) SPDR(R) Portfolio S&P 600(TM) S… SPDR SERIES TRUST	SPSM	$34.14M	0.25%	847,020 NS	FIGI
iShares S&P Small-Cap 600 Growth ETF iShares Trust	IJT	$32.56M	0.50%	807,704 NS	FIGI
iShares Russell Mid-Cap Growth ETF iShares Trust	IWP	$25.54M	0.14%	633,515 NS	FIGI
VANGUARD TAX-MANAGED SMALL-CAP FUND VANGUARD TAX-MANAGED FUNDS	—	$24.82M	0.26%	615,785 NS	FIGI
State Street(R) SPDR(R) S & P 600(TM) Small Cap… SPDR SERIES TRUST	SLYG	$19.91M	0.50%	493,859 NS	FIGI
VIP Mid Cap Portfolio Variable Insurance Products Fund III	—	$17.26M	0.22%	428,200 NS	FIGI
iShares Russell 1000 Growth ETF iShares Trust	IWF	$15.28M	0.01%	378,947 NS	FIGI
iShares Russell Mid-Cap ETF iShares Trust	IWR	$14.51M	0.03%	359,976 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCORT
FIGI_COMPOSITEBBG000BKJG33
FIGI_SHARE_CLASSBBG001S8QGV1
CIK0001088856
ISINUS2183521028
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Corcept Therapeutics is a biopharmaceutical company focused on developing drugs for metabolic and psychiatric disorders, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.